HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe | Zendy

Cleophas Chimbetete | Zendy; David Katzenstein | Zendy; Tinei Shamu | Zendy; Adrian Spoerri | Zendy; Janne Estill | Zendy; Matthias Egger | Zendy; Olivia Keiser | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe

Author(s) -

Cleophas Chimbetete,

David Katzenstein,

Tinei Shamu,

Adrian Spoerri,

Janne Estill,

Matthias Egger,

Olivia Keiser

Publication year - 2018

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofy005

Subject(s) - medicine , abacavir , darunavir , interquartile range , lamivudine , lopinavir , dolutegravir , raltegravir , viral load , zidovudine , drug resistance , odds ratio , confidence interval , hiv drug resistance , ritonavir , gastroenterology , reverse transcriptase inhibitor , efavirenz , virology , antiretroviral therapy , human immunodeficiency virus (hiv) , virus , viral disease , hepatitis b virus , microbiology and biotechnology , biology

The prevelance of PI mutations was high. Adolescents and young adults had a lower risk of acquiring major PI resistance mutations, possibly due to poor adherence to ART. Third-line treatment with a regimen of Darunavir/r, Raltegravir/Dolutegravir, and optimized nucleoside reverse transcriptase inhibitors was effective.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research